Altitude Lab Portfolio: NephroNovus
source confidence: Low status: Useful updated 2026-08-11
Summary
Altitude Lab's public portfolio lists NephroNovus as a therapeutics company estimated founded in 2023, categorized as Alumni, with a one-line description of chronic kidney disease drug discovery combining biochemical pathway exploration and computational techniques. A linked resident story by co-founder Kevin Yang (April 2025) adds founder narrative and a stated focus on renal fibrosis but is not a pipeline or funding disclosure.
Useful Claims
- Portfolio entry name: NephroNovus.
- Listed industry: Therapeutics.
- Listed estimated founding year: 2023.
- Listed Altitude Lab status: Alumni (not currently listed as Resident).
- Portfolio tagline: "Pioneering the battle against chronic kidney disease by exploring groundbreaking biochemical pathways and utilizing advanced computational techniques."
- A linked Altitude Lab resident story by Kevin Yang states NephroNovus targets renal fibrosis as a driver of chronic kidney disease progression and describes a father–son co-founding team — per the linked resident story, not this portfolio capture.
- A minimal site at
https://www.nephronovus.com/exists (branding/placeholder layout only); this capture does not include that site.
Verbatim
"Pioneering the battle against chronic kidney disease by exploring groundbreaking biochemical pathways and utilizing advanced computational techniques." — Portfolio page, NephroNovus entry
"NephroNovus" — Portfolio page, company name
"Therapeutics" — Portfolio page, industry tag
"Alumni" — Portfolio page, status tag
"Est. 2023" — Portfolio page, founding year
Reliability Notes
Portfolio listings validate incubator association and high-level positioning, not clinical data, financing, or reproducible science. Alumni status suggests the company completed or exited Altitude Lab residency, but does not establish its current operating status. Resident-story claims about renal fibrosis and the co-founding team come from a separate Altitude Lab article linked in See Also; they are not present in this portfolio capture. No peer-reviewed publications, patents, or regulatory filings tying specific assets to NephroNovus were captured in this source record. Team size, disclosed funding, and lead compounds remain unknown in primary materials reviewed.
Related Pages
See Also
- Building a Startup with My Dad: Lessons in Family, Boundaries, and Trust · https://altitudelab.org/articles/building-a-startup-with-my-dad-lessons-in-family-boundaries-and-trust — Altitude Lab resident story with renal-fibrosis mission statement (narrative, not technical evidence)